These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 26099473)

  • 21. Contrast-enhanced ultrasound with perflubutane microbubble agent: evaluation of differentiation of hepatocellular carcinoma.
    Takahashi M; Maruyama H; Ishibashi H; Yoshikawa M; Yokosuka O
    AJR Am J Roentgenol; 2011 Feb; 196(2):W123-31. PubMed ID: 21257852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential Diagnosis of Arterial Phase Enhanced Hepatic Inflammatory Lesions and Hepatocellular Carcinomas with Contrast-enhanced Ultrasound.
    Yang W; Yan K; Wang S; Dai Y; Wu W; Yin SS; Chen MH
    Ultrasound Med Biol; 2016 Jan; 42(1):82-91. PubMed ID: 26456578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio.
    Wen YL; Kudo M; Zheng RQ; Ding H; Zhou P; Minami Y; Chung H; Kitano M; Kawasaki T; Maekawa K
    AJR Am J Roentgenol; 2004 Apr; 182(4):1019-26. PubMed ID: 15039180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid.
    Hatanaka K; Kudo M; Minami Y; Ueda T; Tatsumi C; Kitai S; Takahashi S; Inoue T; Hagiwara S; Chung H; Ueshima K; Maekawa K
    Intervirology; 2008; 51 Suppl 1():61-9. PubMed ID: 18544950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of fusion imaging combining contrast-enhanced ultrasonography with a perflubutane-based contrast agent and contrast-enhanced computed tomography for the evaluation of percutaneous radiofrequency ablation of hypervascular hepatocellular carcinoma.
    Numata K; Fukuda H; Morimoto M; Kondo M; Nozaki A; Oshima T; Okada M; Takebayashi S; Maeda S; Tanaka K
    Eur J Radiol; 2012 Oct; 81(10):2746-53. PubMed ID: 22197088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma.
    Numata K; Fukuda H; Miwa H; Ishii T; Moriya S; Kondo M; Nozaki A; Morimoto M; Okada M; Takebayashi S; Maeda S; Nozawa A; Nakano M; Tanaka K
    Eur J Radiol; 2014 Jan; 83(1):95-102. PubMed ID: 24176532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of liver lesions by real-time contrast-enhanced ultrasonography.
    Celli N; Gaiani S; Piscaglia F; Zironi G; Camaggi V; Leoni S; Righini R; Bolondi L
    Eur J Gastroenterol Hepatol; 2007 Jan; 19(1):3-14. PubMed ID: 17206071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential diagnosis of hepatic tumors by using contrast enhancement patterns at US.
    Isozaki T; Numata K; Kiba T; Hara K; Morimoto M; Sakaguchi T; Sekihara H; Kubota T; Shimada H; Morizane T; Tanaka K
    Radiology; 2003 Dec; 229(3):798-805. PubMed ID: 14563903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis.
    Kobayashi M; Ikeda K; Hosaka T; Sezaki H; Someya T; Akuta N; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Kumada H
    Cancer; 2006 Feb; 106(3):636-47. PubMed ID: 16369988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small hepatocellular carcinomas in cirrhosis: differences in contrast enhancement effects between helical CT and MR imaging during multiphasic dynamic imaging.
    Hayashida M; Ito K; Fujita T; Shimizu A; Sasaki K; Tanabe M; Matsunaga N
    Magn Reson Imaging; 2008 Jan; 26(1):65-71. PubMed ID: 17566685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison Between Low Mechanical Index and High Mechanical Index Contrast Modes of Contrast-Enhanced Ultrasonography: Evaluation of Perfusion Defects of Hypervascular Hepatocellular Carcinomas During the Post-Vascular Phase.
    Duisyenbi Z; Numata K; Nihonmatsu H; Fukuda H; Chuma M; Kondo M; Nozaki A; Tanaka K; Maeda S
    J Ultrasound Med; 2019 Sep; 38(9):2329-2338. PubMed ID: 30653696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted?
    Leoni S; Piscaglia F; Granito A; Borghi A; Galassi M; Marinelli S; Terzi E; Bolondi L
    Ultraschall Med; 2013 Jun; 34(3):280-7. PubMed ID: 23616066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneity of microbubble accumulation: a novel approach to discriminate between well-differentiated hepatocellular carcinomas and regenerative nodules.
    Maruyama H; Takahashi M; Sekimoto T; Kamesaki H; Shimada T; Kanai F; Yokosuka O
    Ultrasound Med Biol; 2012 Mar; 38(3):383-8. PubMed ID: 22261511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence.
    Quaia E; Calliada F; Bertolotto M; Rossi S; Garioni L; Rosa L; Pozzi-Mucelli R
    Radiology; 2004 Aug; 232(2):420-30. PubMed ID: 15286314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contrast-enhanced ultrasound for the differentiation of small atypical hepatocellular carcinomas from dysplastic nodules in cirrhosis.
    Shin SK; Kim YS; Choi SJ; Shim YS; Jung DH; Kwon OS; Choi DJ; Kim JH
    Dig Liver Dis; 2015 Sep; 47(9):775-82. PubMed ID: 26043653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in Chronic Liver Disease: Diffusion-weighted Imaging for Characterization.
    Hwang J; Kim YK; Jeong WK; Choi D; Rhim H; Lee WJ
    Radiology; 2015 Jul; 276(1):137-46. PubMed ID: 25734551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of contrast-enhanced ultrasonography with dynamic flow imaging to evaluate therapeutic effects for hepatocellular carcinoma.
    Hotta N; Tagaya T; Maeno T; Ishikawa T; Okumura A; Fukuzawa Y; Kakumu S
    Hepatogastroenterology; 2003; 50(54):1867-71. PubMed ID: 14696421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentiation of regenerative nodule, dysplastic nodule, and small hepatocellular carcinoma in cirrhotic patients: a contrast-enhanced ultrasound-based multivariable model analysis.
    Duan Y; Xie X; Li Q; Mercaldo N; Samir AE; Kuang M; Lin M
    Eur Radiol; 2020 Sep; 30(9):4741-4751. PubMed ID: 32307563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging.
    Gatto A; De Gaetano AM; Giuga M; Ciresa M; Siciliani L; Miele L; Riccardi L; Pizzolante F; Rapaccini GL; Gasbarrini A; Giuliante F; Vecchio FM; Pompili M; Bonomo L
    Abdom Imaging; 2013 Aug; 38(4):736-44. PubMed ID: 22986351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranodular signal intensity analysis of hypovascular high-risk borderline lesions of HCC that illustrate multi-step hepatocarcinogenesis within the nodule on Gd-EOB-DTPA-enhanced MRI.
    Kobayashi S; Matsui O; Gabata T; Koda W; Minami T; Ryu Y; Kozaka K; Kitao A
    Eur J Radiol; 2012 Dec; 81(12):3839-45. PubMed ID: 22884705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.